Listenly

How should procurement manage costs when biotech companies scale from early-stage to clinical trials?

Answered at 18:00 in Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast

— questions searchable right now

How should procurement manage costs when biotech companies scale from early-stage to clinical trials?

Companies may scale spending from $20 million annually to $40 million, then $80 million, $100 million, and potentially $200 million per year in drug development. Procurement needs more structured finance, legal, and formal agreements as budgets grow, with provisions for controlled costs, pass-through costs, and areas for adjustment when unknowns occur during trials.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Companies may scale spending from $20 million annually to $40 million, then $80 million, $100 million, and potentially $200 million per year in drug development.

Dave Stowe, Founder and Managing Partner at Adventus · Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast · answer at 18:00

Key takeaways

  • Companies may scale spending from $20 million annually to $40 million, then $80 million, $100 million, and potentially $200 million per year in drug development.

Quote to remember

“Somehow you've got to build those relationships. And I feel like when I've seen bad situations happen is people in the pharma space and the finance procurement do not extend it. They say, well, they should come and find me. And I'd say, no, it's the other way around. We need to go to them.”

— Dave Stowe

The full answer · about 1 min

Companies may scale spending from $20 million annually to $40 million, then $80 million, $100 million, and potentially $200 million per year in drug development. Procurement needs more structured finance, legal, and formal agreements as budgets grow, with provisions for controlled costs, pass-through costs, and areas for adjustment when unknowns occur during trials.

Key facts

  • Three main phases of clinical trials: Phase One, Two, and Three
  • Biotech spending scale progression: $20 million to $40 million to $80 million to $100 million to $200 million annually in drug development
  • Viagra development timeline: designed for heart treatment over 20 years ago before pivoting to different therapeutic use
  • Preclinical stage triggers: investigational new drug (IND) setup marks transition requiring more investor money and structured relationships
  • Patent protection: limited time period for pharmaceutical companies to recoup investments before drugs lose patent exclusivity and become subject to generic competition

People, companies and topics mentioned

AdventusContract Research Organizations (CROs)PwCOliver WymanHorizon TherapeuticsPurdue PharmaFDAInvestigational New Drug (IND)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00